Despite the challenging fundraising environment, we are witnessing significant investments in AI-...

Despite the challenging fundraising environment, we are witnessing significant investments in AI-enabled drug discovery and development.

Following Sanofi's recent partnership with OpenAI and Formation Bio (that some of you may remember as TrialSpark), the latter has taken a notable step by securing nearly $400M in their Series D funding round. This funding, aimed at enhancing their AI platform and in-licensing new product candidates, highlights the growing confidence in AI-driven healthcare innovations.

This deal, much like the recent emergence of Xaira Therapeutics from stealth mode, highlights the latest fierce battleground among major VC funds. With A16Z backing Formation Bio, and Lightspeed and NEA investing in Xaira, the competition to lead in AI-powered biotech innovations is intensifying. Sequoia has even decided to back both ventures.